Author of

• 16831

  +

  P1.06 - Poster Session with Presenters Present (ID 458)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16849

    +

    P1.06-018 - Treatment Patterns and Clinical Practices of Advanced (Stage IV) Non-Small Cell Lung Cancer (NSCLC) in Europe - A Structured Literature Review (ID 4369)

    14:30 - 14:30  |  Author(s): J. Amelio
    • Abstract

    Background:
    Non-small cell lung cancer (NSCLC) is associated with high mortality and a poor five-year survival. Novel therapies in the pipeline hold promise to address these unmet needs and improve prognosis. Furthermore, their introduction is expected to bring considerable changes to the European treatment landscape. The aim of this review is to provide an overview of the current treatment patterns for advanced (stage IV) NSCLC across five European countries (EU5; France, Germany, Italy, Spain and the UK).
    
    Methods:
    A structured literature search was conducted in electronic databases for studies published between January 2010 and February 2016 to identify publications reporting on treatments for stage IV NSCLC in European populations. Additional literature searches of relevant European conferences and internet-based sources were performed to ensure the most up-to-date evidence and published clinical guidelines in the EU5 countries were captured.
    
    Results:
    A total of nine relevant articles (five full-text studies and four conference abstracts) as well as ten clinical guidelines were eligible for inclusion in the literature review. All publications identified were observational studies of advanced NSCLC treatment patterns in the EU5 with data collected between 2005 and 2014. The most commonly reported first-line treatments were cisplatin, carboplatin and pemetrexed, a trend supported by data from individual countries where platinum-based regimens were the most widely prescribed. Other systemic treatments received included non-platinum based regimens, bevacizumab and investigational drugs. The most common second- and third-line treatment options were docetaxel, erlotinib and gemcitabine. There was limited published literature on lines of treatment prescribed in the UK whereby only information on second-line prescribed therapies was available. These included docetaxel, erlotinib, and pemetrexed. Based on this data, treatment patterns appear to be in-line with recommendations from European and national guidelines of NSCLC treatments with the exception of crizotinib and afatinib, which were not approved at the time of the data collection for the majority of studies included in the literature review.
    
    Conclusion:
    Treatment practices in advanced NSCLC are similar across EU5 countries with slight variations depending on the time period assessed and most notably on the approval and availability of novel therapies. Overall, treatments reported as part of clinical practices across EU5 countries prior to 2010 are still recommended by both national and European-wide guidelines. Furthermore, there is a paucity of comprehensive treatment patterns information for the UK.